Categories Health Care

Soliton spikes over 50% on its decision to proceed with cellulite trials

Shares of Soliton Inc. (NASDAQ: SOLY) jumped over 50% during the morning trade on Wednesday after the medical device company said in a statement that it would move forward with the pivotal trial of its Rapid Acoustic Pulse (RAP) device for the treatment of cellulite.

The Houston-based firm said the decision was based on the positive data from its proof of concept (POC) clinical trial. In the POC trial, the range of improvement in cellulite severity score was 20% to 47% and the average improvement for all patients was nearly a 30% improvement, the company said.

soliton tattoo removal device FDA
Image for representation. Photo by Allef Vinicius on Unsplash

The pivotal trial is expected to begin within three months. The RAP device had earlier received clearance from the US Food and Drug Administration (FDA) for the purpose of tattoo removal, according to Soliton.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

“The market for non-invasive cellulite treatments is about $1 billion in the US, so it is clear that many women who are affected by the condition are interested in finding ways to reduce or eliminate it,” said co-founder Walter Klemp.

In February this year, the company had a Regulation A+ IPO, meaning it raised money from public funding. SOLY shares have almost tripled since then, despite criticisms that the company is driving the stock with regular meaningless updates.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Key highlights from Johnson & Johnson’s (JNJ) Q2 2025 earnings results

Johnson & Johnson (NYSE: JNJ) reported its second quarter 2025 earnings results today. Reported sales increased 5.8% year-over-year to $23.7 billion. Operational sales growth was 4.6%. Net earnings grew over

Hasbro (HAS) Earnings Preview: What to expect from the Q2 2025 report

Shares of Hasbro, Inc. (NASDAQ: HAS) stayed red on Tuesday. The stock has gained 43% over the past three months. The toy company is scheduled to report its earnings results

Citigroup (C) Q2 FY25 earnings rise on higher revenues, beat estimates

Banking giant Citigroup Inc. (NYSE: C) reported higher revenues and earnings for the second quarter of fiscal 2025. The numbers also exceeded Wall Street's estimates. Net income increased to $4.0

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top